Application 761145

Type
BLA
Sponsor
JANSSEN BIOTECH

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761145Darzalex Fasprodaratumumab and hyaluronidase-fihj351(a)Rx2026-06-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001DARZALEX FASPRODARATUMUMAB;HYALURONIDASE-FIHJINJECTABLE;INJECTION120MG;2000UNITS/MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Darzalex FasproDARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)Janssen Biotech, Inc.4bb241af-4299-4373-8762-2d6709515db02026-02-11Warnings, Adverse reactionsExact identifier
application number: BLA761145
ndc (product): 57894-503

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 15 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab, hyaluronidase (human recombinant), histidine, histidine monohydrochloride monohydrate, methionine, polysorbate 20, and sorbitolJanssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent
57894-503Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)Janssen Biotech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85140SUPPL 2026-02-24
85045SUPPL 2026-02-13
84860SUPPL 2026-01-28
84852SUPPL 2026-01-28
84256SUPPL 2025-11-21
84247SUPPL 2025-11-21
84236SUPPL 2025-11-20
84187SUPPL 2025-11-18
84176SUPPL 2025-11-17
84127SUPPL 2025-11-07
84124SUPPL 2025-11-07
79256SUPPL 2024-07-31
79262SUPPL 2024-07-30
72560SUPPL2022-11-04
72552SUPPL2022-11-03
69972SUPPL2022-01-26
69963SUPPL2022-01-25
69435SUPPL2021-12-01
69429SUPPL2021-12-01
68054SUPPL2021-07-13
68044SUPPL2021-07-12
67592ORIG2021-05-26
66789SUPPL2021-03-16
66782SUPPL2021-03-15
66218SUPPL2021-02-16
66165SUPPL2021-02-09
66029SUPPL2021-02-01
65918SUPPL2021-01-15
65908SUPPL2021-01-14
62823ORIG2020-05-05
62799ORIG2020-05-01